These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32522803)

  • 1. Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma.
    Cissé MY; Pyrdziak S; Firmin N; Gayte L; Heuillet M; Bellvert F; Fuentes M; Delpech H; Riscal R; Arena G; Chibon F; Le Gellec S; Maran-Gonzalez A; Chateau MC; Theillet C; Carrere S; Portais JC; Le Cam L; Linares LK
    Sci Transl Med; 2020 Jun; 12(547):. PubMed ID: 32522803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.
    Ou WB; Zhu J; Eilers G; Li X; Kuang Y; Liu L; Mariño-Enríquez A; Yan Z; Li H; Meng F; Zhou H; Sheng Q; Fletcher JA
    Oncotarget; 2015 Apr; 6(12):10510-20. PubMed ID: 25888633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A metabolic crosstalk between liposarcoma and muscle sustains tumor growth.
    Manteaux G; Amsel A; Riquier-Morcant B; Prieto Romero J; Gayte L; Fourneaux B; Larroque M; Gruel N; Quignot C; Perot G; Jacq S; Cisse MY; Pomiès P; Sengenes C; Chibon F; Heuillet M; Bellvert F; Watson S; Carrere S; Firmin N; Riscal R; Linares LK
    Nat Commun; 2024 Sep; 15(1):7940. PubMed ID: 39266552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway.
    Ludwig MP; Galbraith MD; Eduthan NP; Hill AA; Clay MR; Tellez CM; Wilky BA; Elias A; Espinosa JM; Sullivan KD
    Cancer Res; 2023 Aug; 83(15):2543-2556. PubMed ID: 37205634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
    Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
    Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
    Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O
    Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
    Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
    Ray-Coquard I; Blay JY; Italiano A; Le Cesne A; Penel N; Zhi J; Heil F; Rueger R; Graves B; Ding M; Geho D; Middleton SA; Vassilev LT; Nichols GL; Bui BN
    Lancet Oncol; 2012 Nov; 13(11):1133-40. PubMed ID: 23084521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.
    Butò S; Pierotti MA; Tamborini E; Della Torre G; Lavarino C; Rilke F; Pilotti S
    Diagn Mol Pathol; 1999 Sep; 8(3):125-30. PubMed ID: 10565683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
    Somaiah N; Tap W
    Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
    Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
    J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.
    Schöffski P; Lahmar M; Lucarelli A; Maki RG
    Future Oncol; 2023 Mar; 19(9):621-629. PubMed ID: 36987836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma.
    Dei Tos AP; Doglioni C; Piccinin S; Maestro R; Mentzel T; Barbareschi M; Boiocchi M; Fletcher CD
    J Pathol; 1997 Jan; 181(1):8-13. PubMed ID: 9071997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53.
    Riscal R; Schrepfer E; Arena G; Cissé MY; Bellvert F; Heuillet M; Rambow F; Bonneil E; Sabourdy F; Vincent C; Ait-Arsa I; Levade T; Thibaut P; Marine JC; Portais JC; Sarry JE; Le Cam L; Linares LK
    Mol Cell; 2016 Jun; 62(6):890-902. PubMed ID: 27264869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
    Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
    Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
    Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
    Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
    Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
    J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.